The Latest Breaking News from Benzinga

Novo Nordisk A/S (NYSE:NVO) shouldn't be trading like a meme stock — not when it's sitting on deep-value fundamentals, a GLP-1 fortress, and a pipeline pivot that could flip 2026 from bruised to breakout. Yet here we are: a 69% reset, sentiment in shambles, and a business that looks nothing…

Despite reporting one of the most spectacular earnings quarters in its history, NVIDIA Corp. (NASDAQ:NVDA) is on track to end November with its worst monthly performance in over three years, raising fresh questions about whether the chipmaker’s AI-fueled rally has hit a wall.

Billionaire Lawyer John Morgan believes the growing gulf between rich and poor Americans poses the nation’s gravest threat, yet his approach to solving it sparked fierce pushback during a July appearance on Jubilee’s video series where strangers confronted him about his wealth.

Wall Street's sector rotation entered full throttle Tuesday, with investors pouring into previously overlooked corners of the market amid an AI-driven shift that now favors undervalued small caps and defensive names such as health care.

Global stock markets may look stretched by traditional valuation measures, but Schroders argues that investors are underestimating the structural forces that could keep prices elevated—and even push them higher.

Tom Lee is sticking to his $7,000 to $9,000 Ethereum (CRYPTO: ETH) target, despite predicting a crash towards $2,500 before the reversal.

A 70-year-old retiree from Cleveland wants to sell her paid-off $425,000 condo to buy a house for her 19-year-old grandson. She called into a recent “The Ramsey Show” to ask if that was the right move.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday.

The U.K.’s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc’s (NASDAQ:AUTL) Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service (NHS) for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).